These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 12769711)

  • 1. Sch-66336 (sarasar) and other benzocycloheptapyridyl farnesyl protein transferase inhibitors: discovery, biology and clinical observations.
    Taveras AG; Kirschmeier P; Baum CM
    Curr Top Med Chem; 2003; 3(10):1103-14. PubMed ID: 12769711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Farnesyl protein transferase inhibition: a novel approach to anti-tumor therapy. the discovery and development of SCH 66336.
    Ganguly AK; Doll RJ; Girijavallabhan VM
    Curr Med Chem; 2001 Oct; 8(12):1419-36. PubMed ID: 11562275
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trihalobenzocycloheptapyridine analogues of Sch 66336 as potent inhibitors of farnesyl protein transferase.
    Njoroge FG; Vibulbhan B; Pinto P; Strickland CL; Bishop WR; Kirschmeir P; Girijavallabhan V; Ganguly AK
    Bioorg Med Chem; 2003 Jan; 11(1):139-43. PubMed ID: 12467716
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of action.
    Jabbour E; Kantarjian H; Cortes J
    Leuk Lymphoma; 2004 Nov; 45(11):2187-95. PubMed ID: 15512806
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Farnesyl transferase inhibitors in the treatment of breast cancer.
    Kelland LR
    Expert Opin Investig Drugs; 2003 Mar; 12(3):413-21. PubMed ID: 12605564
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Exploring the role of bromine at C(10) of (+)-4-[2-[4-(8-chloro-3,10-dibromo- 6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11(R)-yl)-1-piperidinyl]-2- oxoethyl]-1-piperidinecarboxamide (Sch-66336): the discovery of indolocycloheptapyridine inhibitors of farnesyl protein transferase.
    Taveras AG; Aki C; Chao J; Doll RJ; Lalwani T; Girijavallabhan V; Strickland CL; Windsor WT; Weber P; Hollinger F; Snow M; Patton R; Kirschmeier P; James L; Liu M; Nomeir A
    J Med Chem; 2002 Aug; 45(18):3854-64. PubMed ID: 12190309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Farnesyl transferase inhibitors: a major breakthrough in anticancer therapy? Naples, 12 April 2002.
    Caponigro F
    Anticancer Drugs; 2002 Sep; 13(8):891-7. PubMed ID: 12394276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The farnesyl transferase inhibitor SCH 66336 induces a G(2) --> M or G(1) pause in sensitive human tumor cell lines.
    Ashar HR; James L; Gray K; Carr D; McGuirk M; Maxwell E; Black S; Armstrong L; Doll RJ; Taveras AG; Bishop WR; Kirschmeier P
    Exp Cell Res; 2001 Jan; 262(1):17-27. PubMed ID: 11120601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. (+)-4-[2-[4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo[5, 6]cyclohepta[1,2-b]- pyridin-11(R)-yl)-1-piperidinyl]-2-oxo-ethyl]-1-piperidinecarboxamid e (SCH-66336): a very potent farnesyl protein transferase inhibitor as a novel antitumor agent.
    Njoroge FG; Taveras AG; Kelly J; Remiszewski S; Mallams AK; Wolin R; Afonso A; Cooper AB; Rane DF; Liu YT; Wong J; Vibulbhan B; Pinto P; Deskus J; Alvarez CS; del Rosario J; Connolly M; Wang J; Desai J; Rossman RR; Bishop WR; Patton R; Wang L; Kirschmeier P; Ganguly AK
    J Med Chem; 1998 Nov; 41(24):4890-902. PubMed ID: 9822558
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice.
    Liu M; Bryant MS; Chen J; Lee S; Yaremko B; Lipari P; Malkowski M; Ferrari E; Nielsen L; Prioli N; Dell J; Sinha D; Syed J; Korfmacher WA; Nomeir AA; Lin CC; Wang L; Taveras AG; Doll RJ; Njoroge FG; Mallams AK; Remiszewski S; Catino JJ; Girijavallabhan VM; Bishop WR
    Cancer Res; 1998 Nov; 58(21):4947-56. PubMed ID: 9810004
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-activity relationship of 3-substituted N-(pyridinylacetyl)-4- (8-chloro-5,6-dihydro-11H-benzo[5,6]cyclohepta[1,2-b]pyridin-11-ylidene )- piperidine inhibitors of farnesyl-protein transferase: design and synthesis of in vivo active antitumor compounds.
    Njoroge FG; Vibulbhan B; Rane DF; Bishop WR; Petrin J; Patton R; Bryant MS; Chen KJ; Nomeir AA; Lin CC; Liu M; King I; Chen J; Lee S; Yaremko B; Dell J; Lipari P; Malkowski M; Li Z; Catino J; Doll RJ; Girijavallabhan V; Ganguly AK
    J Med Chem; 1997 Dec; 40(26):4290-301. PubMed ID: 9435898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tricyclic farnesyl protein transferase inhibitors: crystallographic and calorimetric studies of structure-activity relationships.
    Strickland CL; Weber PC; Windsor WT; Wu Z; Le HV; Albanese MM; Alvarez CS; Cesarz D; del Rosario J; Deskus J; Mallams AK; Njoroge FG; Piwinski JJ; Remiszewski S; Rossman RR; Taveras AG; Vibulbhan B; Doll RJ; Girijavallabhan VM; Ganguly AK
    J Med Chem; 1999 Jun; 42(12):2125-35. PubMed ID: 10377218
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Farnesyltransferase inhibitors.
    Hahn SM; Bernhard E; McKenna WG
    Semin Oncol; 2001 Oct; 28(5 Suppl 16):86-93. PubMed ID: 11706400
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro study of farnesyltransferase inhibitor SCH 66336, in combination with chemotherapy and radiation, in non-small cell lung cancer cell lines.
    Loprevite M; Favoni RE; De Cupis A; Scolaro T; Semino C; Mazzanti P; Ardizzoni A
    Oncol Rep; 2004 Feb; 11(2):407-14. PubMed ID: 14719076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of a human carcinoma cell line selected for resistance to the farnesyl transferase inhibitor 4-(2-(4-(8-chloro-3,10-dibromo-6,11-dihydro-5H-benzo-(5,6)-cyclohepta(1,2-b)-pyridin-11(R)-yl)-1-piperidinyl)-2-oxo-ethyl)-1-piperidinecarboxamide (SCH66336).
    Bruzek LM; Poynter JN; Kaufmann SH; Adjei AA
    Mol Pharmacol; 2005 Aug; 68(2):477-86. PubMed ID: 15901852
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Perspectives on farnesyl transferase inhibitors in cancer therapy.
    Mazieres J; Pradines A; Favre G
    Cancer Lett; 2004 Apr; 206(2):159-67. PubMed ID: 15013521
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models.
    Lobell RB; Omer CA; Abrams MT; Bhimnathwala HG; Brucker MJ; Buser CA; Davide JP; deSolms SJ; Dinsmore CJ; Ellis-Hutchings MS; Kral AM; Liu D; Lumma WC; Machotka SV; Rands E; Williams TM; Graham SL; Hartman GD; Oliff AI; Heimbrook DC; Kohl NE
    Cancer Res; 2001 Dec; 61(24):8758-68. PubMed ID: 11751396
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Farnesyl transferase inhibitors: mechanism of action, translational studies and clinical evaluation.
    Bishop WR; Kirschmeier P; Baum C
    Cancer Biol Ther; 2003; 2(4 Suppl 1):S96-104. PubMed ID: 14508086
    [No Abstract]   [Full Text] [Related]  

  • 19. Isotype-specific Ras.GTP-levels predict the efficacy of farnesyl transferase inhibitors against human astrocytomas regardless of Ras mutational status.
    Feldkamp MM; Lau N; Roncari L; Guha A
    Cancer Res; 2001 Jun; 61(11):4425-31. PubMed ID: 11389071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A cell-based radioligand binding assay for farnesyl: protein transferase inhibitors.
    Lobell RB; Davide JP; Kohl NE; Burns HD; Eng WS; Gibson RE
    J Biomol Screen; 2003 Aug; 8(4):430-8. PubMed ID: 14567795
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.